AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

AMEERA-1 is a Phase 1/2 open-label single-arm study evaluating once-daily (QD) amcenestrant, an orally bioavailable selective estrogen receptor (ER) degrader, in postmenopausal women with ER+/HER2− advanced breast cancer (NCT03284957), who were mostly heavily pretreated (including targeted therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardia, Aditya, Chandarlapaty, Sarat, Linden, Hannah M., Ulaner, Gary A., Gosselin, Alice, Cartot-Cotton, Sylvaine, Cohen, Patrick, Doroumian, Séverine, Paux, Gautier, Celanovic, Marina, Pelekanou, Vasiliki, Ming, Jeffrey E., Ternès, Nils, Bouaboula, Monsif, Lee, Joon Sang, Bauchet, Anne-Laure, Campone, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284491/
https://www.ncbi.nlm.nih.gov/pubmed/35840573
http://dx.doi.org/10.1038/s41467-022-31668-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284491/
https://www.ncbi.nlm.nih.gov/pubmed/35840573
http://dx.doi.org/10.1038/s41467-022-31668-8

Ejemplares similares